In a report released today, Peter Welford from Jefferies reiterated a Buy rating on Verona Pharma Plc (NASDAQ: VRNA), with a price target of $26. The company’s shares opened today at $13.04.
According to TipRanks.com, Welford is ranked #181 out of 4850 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verona Pharma Plc with a $41 average price target, a 214.4% upside from current levels. In a report issued on August 7, Wedbush also reiterated a Buy rating on the stock with a $56 price target.
.
See today’s analyst top recommended stocks >>
Based on Verona Pharma Plc’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $830.6K. In comparison, last year the company had a GAAP net loss of $4.1 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma’s product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
